Editas Medicine Inc

8EM

Company Profile

  • Business description

    Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

  • Contact

    11 Hurley Street
    CambridgeMA02141
    USA

    T: +1 617 401-9000

    E: [email protected]

    https://www.editasmedicine.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    226

Stocks News & Analysis

stocks

Unconventional wisdom: Are dividends the answers?

As investors toil in complexity the obvious solution may be the right one.
stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,937.7041.70-0.46%
CAC 407,818.2832.15-0.41%
DAX 4024,295.9355.110.23%
Dow JONES (US)44,693.91316.38-0.70%
FTSE 1009,138.3776.880.85%
HKSE25,406.55260.63-1.02%
NASDAQ21,057.9637.940.18%
Nikkei 22541,570.24256.10-0.61%
NZX 50 Index12,875.1570.020.55%
S&P 5006,363.354.440.07%
S&P/ASX 2008,669.4040.00-0.46%
SSE Composite Index3,591.4114.32-0.40%

Market Movers